RE: RE: RE: A Little More Explanation IMO, nothing is coming out between now and the ACC conference (2nd week of March) at which I suspect they will formally present the SUSTAIN trial. Remember, they've only released topline SUSTAIN data thus far. One potential scare from the ASSERT trial was the elevation in liver transaminases during this 12-week treatment period. DM and RVX have mentioned in their blogs/press releases that in the longer SUSTAIN trial that these transaminases came down. So when RVX formally presents this SUSTAIN data, this will alleviate a lot of concerns for the safety of this drug.
So hold on tight until both the AD/PD conference in Florence, IT and the ACC conference in San Francisco, both of which occur in the week of 3/6 to 3/13.
There could also be an embargo from the ACC in effect on RVX discussing the data they plan to present at ACC (https://www.expo.acc.org/acc13/public/Content.aspx?ID=3054&sortMenu=105004). Another possibility is that there is a peer reviewed publication that is already accepted and ready for publication that is part of this embargo, and if and when they present at ACC, there will be new information simultaneously presented as oral presentation, scientific publication, and press releases. Again, this is IMO. One key will be to watch for the RVX meeting abstract to be potenitally published online on March 7 in advance of the ACC meeting (https://accscientificsession.cardiosource.org/ACC/Science/Abstracts-General-Information.aspx). If we DON'T see an abstract from RVX on that list, then my aforementioned embargo scenario seems more likely.
With these two conferences coming up, I really don't see them releasing anything new before the second week of March.